Free tool
FAERS Monitor: Entresto Sprinkle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218591 or its brand name (Entresto Sprinkle, Sacubitril, Valsartan). Reports on generic versions are filed under their own applications.
Reports
116,184
Serious
59,720
51% of reports
Hospitalization
21,241
Death reported
14,200
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension11,679
- death9,164
- dyspnoea9,055
- dizziness8,785
- fatigue8,758
- cough7,892
- wrong technique in product usage process7,341
- weight decreased5,230
- cardiac failure4,550
- malaise4,473
- asthenia3,844
- weight increased3,520
- blood pressure decreased3,216
- product dose omission issue2,873
- myocardial infarction2,793
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 971 |
| 2016 | 6,442 |
| 2017 | 7,878 |
| 2018 | 12,218 |
| 2019 | 12,941 |
| 2020 | 12,382 |
| 2021 | 16,985 |
| 2022 | 19,265 |
| 2023 | 16,689 |
| 2024 | 4,599 |
| 2025 | 3,594 |
| 2026 | 2,216 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,937,975 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypotensionSignal | 11,679 | 11.1 | 10.9 | 102,374 |
| cardiac failureSignal | 4,550 | 10.8 | 10.5 | 38,376 |
| blood pressure decreasedSignal | 3,216 | 9.2 | 8.8 | 22,297 |
| wrong technique in product usage processSignal | 7,341 | 6.8 | 6.6 | 35,106 |
| coughSignal | 7,892 | 5.2 | 5.1 | 26,464 |
| weight decreasedSignal | 5,230 | 3.4 | 3.3 | 8,986 |
| dizzinessSignal | 8,785 | 3.2 | 3.2 | 13,590 |
| myocardial infarctionSignal | 2,793 | 2.9 | 2.8 | 3,519 |
| dyspnoeaSignal | 9,055 | 2.9 | 2.9 | 11,611 |
| weight increasedSignal | 3,520 | 2.9 | 2.8 | 4,280 |
| fatigueSignal | 8,758 | 2.0 | 2.0 | 4,823 |
| death | 9,164 | 1.9 | 1.9 | 4,274 |
| asthenia | 3,844 | 1.9 | 1.8 | 1,538 |
| malaise | 4,473 | 1.9 | 1.8 | 1,781 |
| product dose omission issue | 2,873 | 1.8 | 1.7 | 978 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.